ArticleOxidative medicine and cellular longevity2022
Antioxidant Activity of
Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- A Systematic Review and User Reference of Phenotypic and Molecular Characteristics of Dexamethasone-Mediated C2C12 Muscle Atrophy.Journal of cachexia, sarcopenia and muscle · 2026Pooled it
- Chloroplast genome comparison of Valeriana species with sequence variation, selective pressure, and divergence analysis.PloS one · 2026Article
- Mechanism of Qigu capsule as a treatment for sarcopenia based on network pharmacology and experimental validation.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.Genes & diseases · 2025Article
- Treatment advances of sepsis‑induced myopathy (Review).Biomedical reports · 2025Review
- Plant-Derived Treatments for Different Types of Muscle Atrophy.Phytotherapy research : PTR · 2025Review
- 3-(4-Hydroxy-3-methoxyphenyl) propionic acid mitigates dexamethasone-induced muscle atrophy by attenuating Atrogin-1 and MuRF-1 expression in mouse C2C12 skeletal myotubes.Journal of clinical biochemistry and nutrition · 2025Article
- Molecular mechanism of skeletal muscle loss and its prevention by natural resources.Food science and biotechnology · 2024Review
- Article
- Potential of Lycii Radicis Cortex as an Ameliorative Agent for Skeletal Muscle Atrophy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Nomogram model for predicting frailty of patients with hematologic malignancies - A cross-sectional survey.Asia-Pacific journal of oncology nursing · 2023Article
- Article
- Preventive effects of the butanol fraction ofHeliyon · 2022Article
- Celastrol and Rhynchophylline in the mitigation of simulated muscle atrophy underSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle atrophy is defined as wasting or loss of muscle. Although glucocorticoids (GCs) are well-known anti-inflammatory drugs, their long-term or high-dose use induces skeletal muscle atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.